Tim Worden > Goodwin > Cambridge, England > Lawyer Profile

Goodwin
50-60 Station Road
Cambridge
Cambridgeshire
CB1 2JH
England
Tim Worden photo

Position

Partner

Career

Tim is a partner in Goodwin’s Technology and Life Sciences groups, based in the Cambridge and London offices.

Tim regularly advises life sciences companies on licensing and partnering deals, R&D agreements, clinical trials agreements, distribution agreements, and a broad spectrum of regulatory matters. His expertise also includes advising on the IP and regulatory aspects of M&A transactions, IPOs and venture capital investments. Outside of the life sciences sector, Tim advises technology companies on their technology licensing and commercial agreements.

Tim’s life sciences regulatory expertise includes advising on a broad range of medicinal product and medical device regulatory issues. He also carries out regulatory investigations for clients in the sector, and assists clients with regulatory due diligence in connection with transactions.

Prior to joining Goodwin, he was a partner and co-head of the International Life Sciences group at Taylor Wessing LLP. Tim was previously legal counsel and company secretary at Eli Lilly and Company Limited in the UK. He has a degree in Natural Sciences (Chemistry) from Cambridge.

Education

Diploma, IP Law, 2003 Bristol University; Legal Practice Course, 1998, Nottingham Law School; Post Graduate Diploma in Law, 1997, Nottingham Law School; MA, Natural Sciences, 1996, Cambridge University

Lawyer Rankings

East Anglia > Corporate and commercial > Corporate and commercial: Cambridge

The Cambridge office of Goodwin is an important centre of excellence in the firm’s international network, and it handles high-value M&A and investment transactions for companies in the technology and life sciences sectors. ‘The team is well respected in the market and has extensive knowledge of VC, which means they deliver an excellent product and deal experience‘, remarks one client. Lead partners David Mardle, Malcolm Bates and Tim Worden are acknowledged experts in licensing, M&A, IP commercialisation, financing and regulatory matters. Up-and-coming partners Adam Thatcher and Elizabeth Rhodes  also play key roles in VC and M&A transactions. Thatcher recently assisted shareholders of cloud email security platform Tessian Limited with its acquisition by Proofpoint Inc.

East Anglia > TMT (technology, media and telecoms) > Biotechnology

(Leading partners)

Tim WordenGoodwin

The Cambridge office of Goodwin has a specialist technology and life sciences team that is ‘very engaged, pragmatic and creative, and so able to solve more complex issues‘.  It is part of a global practice that acts for biotechnology companies across the entire corporate lifecycle, as well as advising major venture capital and investment firms. The key practitioners are David Mardle , who has extensive experience in M&A and capital markets; commercial IP specialist Malcolm Bates, who is a key adviser to pioneering small activating RNA (RNAa) therapeutics company MiNA Therapeutics; and contracts expert Tim Worden , who handles licensing and partnering deals, R&D agreements, clinical trials agreements and distribution agreements. Up-and-coming partner Elizabeth Rhodes is also highly recommended.

 

East Anglia > TMT (technology, media and telecoms) > Intellectual property

(Hall of Fame)

Tim Worden – Goodwin

International life sciences firm Goodwin has a strong base in Cambridge, where experienced partners handle IPOs, financings, and patent strategies for a stellar roster of clients. Practice co-heads Malcolm Bates, who focuses on the commercialisation of IP rights, and Tim Worden, who deals with licensing and partnering deals, R&D and clinical trials agreements, are the key contacts. Worden, who is ‘‘very insightful and helpful‘, recently advised Closed Loop Medicine on its global co-development partnership with Pharmanovia, which commercialises novel medicines and revitalizes, extends and expands the lifecycle of established medicines. Associate Georgia Powell is a key adviser on non-contentious IP and commercial matters in the life sciences, technology and healthcare sectors.